Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Accentia Biopharmaceuticals, Inc.
Accentia Reports on Multiple Sclerosis Study: Revimmune Shows Unprecedented Results in Reducing Disability and Improving Functions
July 11th, 2008
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced that researchers from Johns Hopkins University have published encouraging results from a two-year study evaluating the treatment of aggressive relapsing-remitting multiple sclerosis with Revimmune(TM), Accentia's patent-pending, novel usage of an approved chemotherapeutic drug (cyclophosphamide) in an ultra-high dose, pulsed intravenous administration for four hours daily over four days. Administered in this fashion, cyclophosphamide acts as a unique stem-cell sparing myeloablative which can reboot the immune system in order to delete the autoimmunity. Furthermore, Revimmune is believed to be the first therapy in development for...
Source: Health Business Week (2008-07-11)
|
